Locations:
SearchThe deal will expand Strolll’s digital therapeutics platform and see Cleveland Clinic become a shareholder in the company. Lead investigator and Cleveland Clinic inventor, Jay Alberts, PhD, Vice Chair of Innovation in Cleveland Clinic’s Neurological Institute, comments.
Strolll, a pioneer in the field of (AR) digital therapeutics software for neurorehabilitation in Parkinson’s disease, has announced a collaboration with Cleveland Clinic, securing a $3 million investment. As part of the agreement, Cleveland Clinic will gain an exclusive software license and become a shareholder in Strolll. The first phase of this collaboration involves integrating Cleveland Clinic's innovative digital therapeutic software module, DART, into Strolll's platform. DART, which stands for Dual-task Augmented Reality Treatment, is designed to address the challenges faced by Parkinson's patients, particularly in managing postural instability and gait dysfunction, which often lead to falls.
What sets DART apart is its scalability and personalized approach, enabling patients to undergo dual-task training using augmented reality glasses, which simultaneously engage their body and mind through physical and cognitive challenges. The effectiveness of DART has been validated through rigorous evaluation in a randomized controlled trial, marking a significant advancement in the field of digital therapeutics for Parkinson's disease.
“To our knowledge, DART is the first digital therapeutic software for Parkinson’s disease that has undergone rigorous evaluation against an accepted intervention in a randomized controlled trial,” said lead investigator Jay Alberts, PhD, Vice Chair of Innovation in Cleveland Clinic’s Neurological Institute. “These findings suggest that we can address barriers to wider use of dual-task training. The next step is to extend this into the patient’s home. We have an aligned vision for the future of digital therapeutics in neuro-rehab and we’re looking forward to supporting Strolll through this new collaboration.”
Jorgen Ellis, CEO of Strolll, expressed pride in this collaboration and emphasized the company's commitment to leveraging AR technology to revolutionize neuro-rehabilitation, aiming to enhance patient adherence and treatment outcomes while streamlining clinical workflows. As part of this agreement, Strolll will establish its US head office on Cleveland Clinic's main campus, marking a significant milestone in the company's expansion and impact on global healthcare providers and patients.
Read the full article via Med-Tech Innovation News.
